Hyloris Lays Out Ambitious Plans For US
Value Added Medicines Specialist Reveals How It Will Use IPO Proceeds
Fresh from a successful IPO, Belgian value-added medicines specialist Hyloris Pharmaceuticals has the financial firepower it needs to pursue ambitious expansion plans that include building out a US commercial infrastructure, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview.
You may also be interested in...
Value-added medicines specialist Hyloris Pharmaceuticals is launching an IPO to provide the funds it needs to focus on opportunities through the US 505(b)(2) pathway.
Belgian value-added medicines specialist Hyloris Pharmaceuticals says it has raised €15m through a funding round that will give it the firepower to pursue 505(b)(2) applications in the US.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.